The estimated Net Worth of Jonathan Arnold is at least $7.06 Million dollars as of 23 August 2023. Mr. Arnold owns over 87 units of Catalent stock worth over $3,422,702 and over the last 6 years he sold CTLT stock worth over $1,840,234. In addition, he makes $1,797,800 as President - Oral Drug Delivery Solutions at Catalent.
Jonathan has made over 10 trades of the Catalent stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 87 units of CTLT stock worth $3,904 on 23 August 2023.
The largest trade he's ever made was exercising 39,342 units of Catalent stock on 7 October 2020 worth over $1,213,307. On average, Jonathan trades about 2,300 units every 46 days since 2018. As of 23 August 2023 he still owns at least 57,399 units of Catalent stock.
You can see the complete history of Mr. Arnold stock trades at the bottom of the page.
Jonathan Arnold is President - Oral Drug Delivery Solutions of the Company. Mr. Arnold was named President of our Oral Drug Delivery business unit in October 2017. Previously, he served for six years as Vice President and General Manager of our Drug Delivery Solutions business unit. Mr. Arnold’s career in the life sciences contract development and manufacturing organization sector began in 1995, when he joined RP Scherer, a specialist in softgel technologies and now an important part of Catalent, where he served in a variety of international business development and strategic customer account roles over the course of 5 years. Mr. Arnold then spent 11 years working for Patheon, another contract development and manufacturing organization, in multiple different locations, including Italy, the U.K., and Switzerland, serving in roles of increasing responsibility, including Vice President of Global Supply Chain and, ultimately, Chief Procurement Officer, before returning to us in 2011. Prior to working in the life sciences sector, Mr. Arnold had an international business development and strategic marketing role for the U.K.’s largest waste management company, Shanks & McEwan. Mr. Arnold earned his bachelor’s degree in Agricultural, Biochemistry and Nutrition from the University of Newcastle upon Tyne, U.K.
As the President - Oral Drug Delivery Solutions of Catalent, the total compensation of Jonathan Arnold at Catalent is $1,797,800. There are 5 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
Jonathan Arnold is 53, he's been the President - Oral Drug Delivery Solutions of Catalent since 2017. There are 17 older and 10 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Jonathan's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius, and Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: